Higher Incidence Of Sexual Dysfunction Research Articles

Sexual dysfunction in women with breast cancer of Northeast Brazil: a retrospective longitudinal study

Breast cancer treatment leads to physical and psychological changes. The aim of this study was to analyze the incidence of sexual dysfunction and its risk factors in women diagnosed with breast cancer. This retrospective cohort study included women diagnosed and treated for breast cancer (exposed group, n = 90) and healthy women (non-exposed group, n = 93). Data were collected from February 2019 to October 2021 in the state of Rio Grande do Norte (Northeast Brazil), from medical records and using the Female Sexual Function Index (FSFI) questionnaire. Data were collected from medical records and using the Female Sexual Function Index (FSFI) questionnaire. Primary outcomes were analyzed using binary logistic regression. The Mann–Whitney test was used to analyze FSFI domains between groups. The exposed group had a 74% incidence of sexual dysfunction and 3.9 times increased chances of having sexual dysfunction compared with the non-exposed group (OR 3.9, CI 1.8 to 8.2, p < 0.001). Presence of comorbidities increased the chances of sexual dysfunction by 2.5 times (OR 2.5, CI 1.2 to 4.9, p = 0.009). Women diagnosed and treated for breast cancer had a higher incidence of sexual dysfunction than healthy women. Furthermore, comorbidities also increased the chances of sexual dysfunction regardless of exposure to breast cancer.

Посткоитальный цистит как причина сексуальной дисфункции у женщин.

Introduction. Postcoital cystitis is a special form of recurrent cystitis. Against the background of this disease, especially with an aggressive course, the daily activity of patients may change, the quality of life may deteriorate, and sexual dysfunction may develop. Aim. Study the prevalence of sexual dysfunction in patients with recurrent postcoital cystitis, as well as to assess their quality of life. Material and methods. The study compared two groups of patients: the main (first group) and control (second group). The first group included 70 women with recurrent postcoital cystitis. The control group included 70 women without recurrent postcoital cystitis. To assess the prevalence of sexual dysfunction was used: Female Sexual Function Index (FSFI). Patients' quality of life indicators were determined using the SF12v2 questionnaire. Results. The total FSFI score between the groups was statistically significantly different. Sexual dysfunction was detected in patients with recurrent postcoital cystitis in 88.6% of cases, and in 15.7% among women in the control group. Quality of life indicators significantly differed between the groups. More pronounced changes were observed in the mental component of the quality of life. Conclusion. Our data indicate a high incidence of sexual dysfunction in patients with recurrent postcoital cystitis, as well as the impact of postcoital cystitis on the quality of life.

A comparative study of sexual dysfunction in clinically stable schizophrenic patients receiving trifluoperazine, risperidone, and olanzapine

Background: Sexual dysfunction (SD) is a common occurrence in Schizophrenia on antipsychotics, both typical and atypical. Indian studies in this regard are not many in number. Aims and Objectives: The aims of this study were to investigate SD in Schizophrenics on Trifluoperazine, Risperidone, and Olanzapine and also to evaluate the incidence of SD in relation to the duration of illness, duration of treatment, and dosage of the drugs in each group of subjects. Materials and Methods: In stable schizophrenic patients, on Trifluoperazine (n=40), Risperidone (n=40), and Olanzapine (n=40), SD was assessed using Arizona sexual experience scale. Demographic profile and duration of illness, duration of treatment and drug dosage were evaluated in each group. Comparisons were made between the incidence of SD between patients taking typical and atypical antipsychotics. Furthermore, distribution of SD with duration of illness, duration of treatment and dose of drugs were assessed in each group of subjects (taking Trifluoperazine, Risperidone, or Olanzapine). Results: (1) Majority of the subjects were males (66.67%) and above 30 years (55%). (2) Incidence of SD was higher with typical antipsychotics (statistically insignificant). (3) Increased duration of treatment and dose of drugs was associated with higher incidence of SD. Patients treated with Risperidone for longer duration and with Trifluoperazine with higher dose had higher incidence of SD (P&lt;0.05). Conclusion: Incidence of SD is higher in older age groups and with typical Antipsychotics. Increased duration of illness, duration of treatment and higher drug doses, all are associated with higher incidence of SD.

Sexual dysfunction in Brazilian patients with multiple sclerosis

People with multiple sclerosis (PwMS) show an increased risk of sexual dysfunction (SD), both in women and men. The aim of the present study was to apply the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19) and evaluate our results by comparing them with those in in the literature, as well as to assess the ease of applying the scale and the engagement of the patients in discussing the topic of sexuality. We developed and applied a web-based Google form questionnaire that the respondents completed online, which included the MSISQ-19, for the assessment of sexual function. Baseline characteristics were reported as proportions and mean ± standard deviation (SD) or median ± interquartile range (IQR) as appropriate according to data distribution. Categorical variables were stratified by sex and compared with chi-squared tests. Statistical analyses were performed using STATA v. 16 (StataCorp., College Station, TX, USA). Of the 621 respondents, 541 were included in the analysis. Among the patients with MS, a total of 347 (64.14%) exhibited SD. When stratified by gender, the frequencies of SD were not significantly different. There is a high incidence of sexual dysfunction among PwMS and we need to identify the reasons for this and implement strategies to treat and counsel our patients. The MSISQ-19 can be used to help clinicians to assess sexual functioning in a quick and easy way and give patients the possibility to address this topic and receive appropriate help and support.

Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin-A injections improve sexual function?

Interstitial cystitis/bladder pain syndrome (IC/BPS) has a negative impact on female sexual function. We aimed to evaluate the effect of intravesical botulinum toxin-A (BTX-A) injection on the improvement of sexual dysfunction and urinary symptoms using the multi-domain female sexual function Index (FSFI), interstitial cystitis symptom index (ICSI), and interstitial cystitis problem index (ICPI). The data of the 23 patients (study group) who received intravesical BTX-A with the diagnosis of IC/BPS were reviewed. Twenty-three age-matched healthy, sexually active women were determined as the control group. Patients received 100 U BTX-A submucosally injections, including the trigone. One hundred units of BTX-A were diluted to 20 cc0.9% saline, and 1 cc was then applied submucosally on 20 different points of the bladder wall (5 U/1 mL per site). The study group was asked to fill out FSFI, ICSI,andICPI, as well as the visual analog scale (VAS) and bladder diary before and 3 months after the treatment. Patients in the control group completed the same questionnaires once. The pre- and post-treatment questionnaire scores were compared in the study group. The study group's data were also compared to the control group. Compared to the pretreatment period, the study group showed statistically significant improvement in the total FSFI score and each domain of the FSFI after BTX-A injection. The mean total FSFI score and three domains of FSFI (desire, lubrication, pain) reached to the score of the control group following BTX-A injection. Statistically significant improvements were also shown in scores of ICSI, ICPI, and VAS. (p < 0.05). IC/BPS is associated with a very high incidence of sexual dysfunction. Intravesical BTX-A injection may provide significant improvement in sexual dysfunction in women with IC/BPS.

167 (PB-080) Poster - Impact of breast cancer diagnosis on women’s sexuality

Introduction: Breast cancer remains the most frequently diagnosed cancer among in Tunisia representing 20–25% of malignant tumors in women with an incidence in 2017 estimated at 50.17/100 000 cases. Early diagnosis and treatment improves vital prognosis and survival rates on the depend of aesthetic prognosis. The impact of breast cancer on body image should not be underestimated. Physical changes due to oncological therapy are an important issue in long-term breast cancer survivors with a high incidence of sexual dysfunction.

High incidence of sexual dysfunction and timed intercourse was found only in infertile males who with known impairment of sperm quality for a long period: evidence from a hospital-based cross-sectional study

BackgroundInfertile men with higher sexual dysfunction risk and increased psychological burden, were also associated with more inclined to timed intercourse. Decreased semen quality may have adverse effects on male sexual function. However, it is also likely that many of these sequences do not play a direct role, those negative consequences may depend mainly on the later failed attempting pregnancy. Research is limited in this area.MethodsThis cross-sectional study was based on a group of 509 men who were assessed for couple’s infertility at the First Hospital of Jilin University between June 2021 and October 2021. All the men completed a comprehensive questionnaire, and then were divided in two groups. Group A included patients who either never received a routine infertility work-up or done so recently within the last 6 months. Group B included patients who previously received a sperm quality assessment at least 6 months or more prior. Patients were further categorized into three subgroups according to the severity of the decreases in their sperm parameters: severe, mild-moderate, and normozoospermic.ResultsThe prevalence of erectile dysfunction was higher in Group B Mild-Moderate and Group B Severe in comparison to Group A (OR=1.86 [1.07–3.24], P = 0.027; OR=5.312 [2.69–10.49], P < 0.001, respectively). No significant differences were found between Group A and Group B-normozoospermic. Similar results were observed in the prevalence of premature ejaculation between the groups. Timed intercourse was seen in 11.8% (20/170) of men in Group A and 16.2% (19/117) in Group B-normozoospermic. It was more commonly practiced among infertile men in Group B-Mild-Moderate and Group B Severe, as 28.2% (44/156) and 25.7% (17/66) of these couples had attempted to conceive through timed intercourse (P < 0.001).ConclusionsOur findings indicate that the severity of sperm quality impairment was negatively associated with sexual dysfunction only in infertile men who with known impairment of sperm quality for a long period. Timed intercourse was more common among these couples. For those individuals had never test their sperm quality, although more than half of these patients showed a decrease in sperm quality, the incidence of sexual dysfunction is relatively low and were comparable to those men examined previously known as normozoospermic.

Sexual Dysfunction in Patients With Urinary Bladder Stones but no Bladder Outlet Obstruction.

Objective: To explore the correlates of sexual dysfunction and lower urinary tract symptoms (LUTS) in male patients with urinary bladder stones and to determine the effect of stone extraction on recovery of sexual function.Materials and Methods: A total of 87 male patients with primary bladder stones were studied from January 2015 to May 2016. All patients underwent pneumatic lithotripsy for bladder stones. Sexual dysfunction was assessed based on sexual function assessment scales. The relationship of bladder stones with sexual dysfunction or LUTS was assessed using a two-sample t-test. Postoperative improvement of sexual function was assessed by repeated measures Analysis of Variance (ANOVA).Results: Forty-one patients had primary bladder stones and 46 had secondary stones from the kidneys. Eighty-three of 87 patients (95%) had sexual dysfunction; 79 patients (91%) had both sexual dysfunction and LUTS. There was a significant association between bladder stones and sexual dysfunction, between sexual dysfunction and LUTS, and between bladder stone and LUTS (p < 0.05). There was no significant association between the course of illness, size and number of bladder stones, or urinary tract infection with sexual function (p > 0.05). In addition, among 83 patients with both bladder stone and sexual dysfunction, 61 patients (73%) had benign prostatic hyperplasia (BPH) and 22 patients (27%) had no BPH. On postoperative evaluation at 3 months, sexual dysfunction scores were significantly improved in 77 patients (88.5%)Conclusion: Patients with bladder stones have a high incidence of sexual dysfunction, particularly those with co-existing LUTS and BPH. About 1/3 patients without BPH had sexual dysfunction and surgical removal of bladder stones significantly improved sexual function and LUTS.

Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia.

In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and the effect of treating hyperprolactinemia among these patients. In this prospective study, patients were assessed with history, physical examination, hormonal assessment, and two questionnaires, IIEF and AIPE. Patients with hyperprolactinemia received treatment with cabergoline 0.5mg once per week for 6months and were re-evaluated. A total of 102 patients were included in this study, 75 (73.53%) were on hemodialysis, 13 (12.75%) on peritoneal dialysis and 14 (13.73%) on medical treatment alone. Ninety (88.24%) patients had premature ejaculation, 85 (83.33%) had anything from mild-to-moderate-to-severe erectile dysfunction. The incidence of hypogonadism and hyperprolactinemia was 34.4%. Patients treated with cabergoline (n=26) showed a significant increase in LH levels (p=.003) and a significant decrease in prolactin levels (p=.003). Testosterone levels and the incidence of erectile dysfunction or premature ejaculation did not improve significantly. There is a high incidence of sexual dysfunction among patients. Treatment of hyperprolactinemia is effective in correcting prolactin levels, but does not improve erectile dysfunction or premature ejaculation. Therefore, treating hyperprolactinemia is not an overall effective treatment for erectile dysfunction in these patients.

146P Impact of breast cancer treatment on sexual health in pre-menopausal women

With increasing awareness and provision of better treatment modalities, younger women with breast cancer have increased survival. However, due to long term treatment related side effects, they experience an overall decline in sexual health. The study aimed to analyze the incidence of sexual dysfunction in breast cancer survivors and the impact of various treatment modalities on female sexuality. All non-metastatic pre-menopausal women diagnosed with breast cancer or undergoing therapy for breast cancer were enrolled in the study between January to December 2020; and were assessed by Female Sexual Function Index questionnaire (FSFI) before starting therapy, immediately (4 weeks) after completion of therapy and at 3 months follow up. Comparison of FSFI scores between patients who underwent mastectomy versus breast conservation surgery (BCS) and patients on hormonal therapy versus non-hormonal therapy on follow up was done. A total of 150 patients were included in the study. Seventy percent patients underwent mastectomy (n=104) and the rest underwent BCS (n=46). Based on the cut off of 26.55, 82.6% (124) patients had persisting sexual dysfunction at 3 months post treatment. The median scores of BCS group was significantly better than mastectomy group at 3 months (22.85 +/- 2.19 versus 21.75 +/- 2.09, p= 0.002). When individual domains were compared between the two groups at 3 months, arousal, lubrication, orgasm and pain showed more reduction in patients undergoing MRM as compared to BCS, however the differences were not statistically significant. Median FSFI scores were comparable in patients receiving hormonal therapy, versus non- hormonal therapy group (22.3 +/- 2.15 versus 21.9 +/- 2.23, p=0.718). When individual domain were compared desire, arousal and pain showed more reduction in hormonal group as compared to non-hormonal group, however the differences were not statistically significant. Overall, high incidence of sexual dysfunction was seen in breast cancer survivors, which was significantly more in patients who underwent mastectomy. Further studies are needed to address sexual dysfunction in breast cancer survivors and measures to alleviate the same.

Penile Cancer: Managing Sexual Dysfunction and Improving Quality of Life After Therapy.

To review the most current literature on how the treatment for penile cancer can affect quality of life and to discuss current treatment options to overcome sexual dysfunction and ultimately improve patient wellbeing. Multiple medical and surgical therapies exist to address the high incidence of sexual dysfunction following penile cancer treatment. Advancements and refinements in the neophalloplasty, penile prosthesis, and penile lengthening procedures have opened the door to improved long-term outcomes. Additionally, studies continue to highlight the severe psychological toll that penile cancer treatment can have on patients. We explore the potential options for addressing the inherent psychologic effects of these treatments and highlight the need for further research in this domain. Although rare, it is important for all urologists to be familiar with the treatments and post-treatment sequelae of penile cancer. Penile cancer is associated with dramatic decline in quality of life and sexual function. Multiple medical and surgical therapies exist that addresses these concerns. Additionally, urologists must also be mindful of the psychologic component regarding surgical disfigurement and the decline in sexual function.

Sexual Dysfunction and Abnormal Androgen Level after Hematopoietic Stem Cell Transplantation

Introduction: Hematopoietic stem cell transplantation (HSCT) is a potentially curative or consolidative therapy for a large number of hematological diseases. Sexual dysfunction (SD) and abnormal level of the sexual hormone are common in patients after HSCT, which are usually caused by intensive myeloablative conditioning. The change of sexual hormone level and SD resulted in the poor quality of life in this population after transplantation. The current aims of this study were to determine: (i) the incidence rate of SD and the association with androgen post both autologous (auto) and allogeneic (allo) HSCT; (ii) multi-factors analysis between SD and clinical characteristics, primary diease, donor type, cGVHD, etc; (iii) the association of androgen with cGVHD and glucocorticoid (GC) therapy. Methods: From April 2010 to February 2019, a total of 126 (74 males and 52 females) patients with hematological diseases undergoing HSCT were enrolled in our study. The reason for the small sample of patients was that only 126 patients completed our Sexual Function Questionnaire. Controls were 108 healthy, age and gender matched persons came from Medical Examiniation Center of our hospital. Assessment indexes included clinical characteristics, donor type, GVHD incidence, sex hormone levels, and Sexual Functioning Questionnaire (SFQ). The SFQ was implemented by the team members of our research group through a telephone interview, email, paper letter, and WeChat. All of the information and privacy of each patient was strictly conserved. Results: 1. Clinical characteristics of the 126 patients who underwent HSCT were shown in Table 1. The median age of the patients was 38 years old (range 16-66) and the follow up after HSCT was from 6 months to 7 years. The predominant disease spectra were multiple myeloma (MM) and acute leukemia in auto- and allo-HSCT group, respectively. Our results showed a significant difference in gender (P&lt;0.004), donor type (P&lt;0.004), and GVHD development (P&lt;0.0001), indicating a higher incidence of SD when we included these indicators into our analysis. There was no singficant difference of SD development in age, education background, annual family income, primary disease, time post HSCT, and phycological state. 2. Figure 1 showed a higher incidence of SD in both female and male patients after HSCT compared to the healthy controls (P&lt;0.001). Most of them complained that they had trouble in normal sex life and sexual function had not yet recovered to the pre-transplantation level. Moreover, female patients exhibited much significantly decline in overall sexual function (OSD) than the male group (P&lt;0.004). As depicted in the figure 2a and 2b, 54% female and 44% of male developed at least one physical sexual problem. Almost all of the female patients of childbearing age were infertility, and only a small number of young (&lt; 30 years) male patients post transplantation could store fertility (data not shown). 3. From the foregoing data analysis, we confirmed that patients after allo-HSCT with or without GVHD usually acompanied with a higher incidence of SD compared to auto-HSCT group (Table 2). Female patients undergoing allo-HSCT who developed SD had a significantly lower level of androgen (P = 0.02, Table 3a), and that of the male patients was lower compared to healthy control with no significance (Table 3b). Female patients diagnosed with cGVHD had much lower adrongen level, especially in those received GC therapy (Table 4). 4. Although some young female patients had been given regular leuprolide injection every 28 days during their chemotherapy period or pre-transplantation, no significant difference was observed both in SD incidence and androgen level (P &gt; 0.05, due to a small sample, data not shown here). Conclusions: Our results here indicated SD remained a major obstacle for patients to have a better quality of life after HSCT. We should pay more attention to the female patients because they might be at a higher risk to develop SD, especially in those underwent cGVHD and received GC therapy. To improve the sexual function for this population, more intervention methods including optimization of conditioning, better controlling of cGVHD, and reproductive function reservation might be helpful to reduce the incidence of SD. Finally, our study suggested that low androgen levels may contribute to SD and androgen replacement therapy might be a promising choice to improve OSD for patients undergoing HSCT. Disclosures No relevant conflicts of interest to declare.

Sexual dysfunction and associated factors among patients with epilepsy at Amanuel Mental Specialty Hospital, Addis Ababa \u2013 Ethiopia

BackgroundMany patients with chronic illness have sexual dysfunction that may be related to the condition itself, drug side effects, emotional sequel, or a combination of those factors. Patients with epilepsy are no exception. Men and women with epilepsy are frequently complaining sexual dysfunction and they appear to have a higher incidence of sexual dysfunction than peoples with other chronic neurologic illness. These problems can have a substantial impact on their sexuality thus; it needs careful study and evaluation.MethodsHospital based cross sectional study was conducted from January to July, 2016 among Patient with Epilepsy at Amanuel Mental Specialty Hospital. Interviewer administered Changes in Sexual Functioning Questionnaire (CSFQ-14) was used in order to assess the sexual problems. Finally, the data was analyzed by using Statistical Package for Social Science (SPSS) V-20. Descriptive statistics and logistic regression were used to describe the variables. Levels of significance of association determined at < 0.05.ResultsA total of 694 respondents participated, with response rate 99.14%. Among them 576 completed all items. The result showed that 363 subjects (63.9, 95%CI = 59.5–67.7) had global sexual dysfunction. Furthermore, the rate of sexual dysfunction was reported as 55.6% (95%CI = 49.1–62.6) and 67.4% (95%CI = 62.8–72.1) in female and male participants, respectively. Among domains of sexual dysfunction; sexual arousal problem (97.8% (95%CI = 95.8–98.3)) and sexual pain problem (11.3% (95%CI = 8.8–13.9)) were the most and the least prevalent sexual dysfunctions respectively. Concerning associated factors; age grouped > 51, depression, being out of relationship or not satisfied with non-sexual aspect of relationship, being jobless and khat use has positive association with sexual dysfunction. By the other side alcohol use, level of education & age groups 18–21 years associated negatively.ConclusionsThe prevalence of sexual dysfunction among patients with epilepsy is very high; its prevalence is more among males than females. Sexual arousal problem and sexual pain problem were the most and the least prevalent sexual dysfunctions respectively.

Sexual dysfunction associated with Sertraline and Mirtazapine : A comparative open label study

Introduction: Antidepressants have become one of the most frequently prescribed drugs in the world. One of the most common side effects impairing the long term compliance for antidepressants is sexual dysfunction. Antidepressants like Sertraline have been associated with higher incidence of sexual dysfunction than Mirtazapine. However, there are studies which show that incidence of sexual dysfunction after use of Mirtazapine may be higher than previously expected. The aim of the study was to assess and compare the incidence of sexual dysfunction after therapy with Sertraline and Mirtazapine in a Nepali population.&#x0D; Material and Method: Patients needing antidepressant therapy but with minimal or no sexual dysfunction at baseline were randomly assigned to either Mirtazapine (n=54, 7.5-30 mg) or Sertraline (n=54, 25-100 mg). Various aspects of sexual functioning at baseline were measured with Change in Sexual Functioning Questionnaire (CSFQ) and the same were reassessed at 4 weeks.&#x0D; Results The incidence of sexual dysfunction seen in 42.9% patients in Sertraline group and 23.7% patients in Mirtazapine group. Sertraline showed significantly greater decline in Orgasm scores than Mirtazapine.&#x0D; Conclusion: Psychiatric referral rate and psychiatry morbidity was low. Sertraline caused significant decline in Orgasm aspect of sexual functioning. Although lesser in propensity, Mirtazapine is not free of adverse effect of sexual dysfunction. More studies are need to further confirm these findings.

Interstitial Cystitis and Sexual Dysfunction: Diagnostic Accuracy Is Essential

To review the current literature regarding sexual dysfunction and interstitial cystitis/bladder pain syndrome (IC/BPS). Our goal was to review the epidemiology and overlap of these two conditions as well discuss the success of various IC/BPS treatment modalities with improving sexual function. Women with IC/BPS have a much higher incidence of sexual dysfunction as compared to controls, and this is often a significant predictor of poor quality of life. IC/BPS is thought to have various phenotypes and is associated with a number of overlapping chronic conditions which may contribute to sexual dysfunction thus making an accurate diagnosis imperative. Various treatments for IC/BPS may improve certain domains of sexual function. It is not surprising that IC/BPS, a chronic pelvic pain condition, negatively affects sexual function. More research is needed not just on the prevalence of sexual dysfunction in this patient population, but specifically on treatment options and ways to improve sexual function in these distressed patients.

Knowledge of women issues and epilepsy among doctors in Sudan

ObjectiveThe objective of this study was to assess the knowledge of doctors in Sudan about women issues related to epilepsy. MethodsIn this cross-sectional study that was conducted in Sudan during the period from October 2017 to December 2017, we used Google forms to collect data from 154 doctors using Knowledge of Women Issues and Epilepsy (KOWIE) II standardized questionnaire. ResultsOur studied group included house officers (n = 34), medical officers (n = 60), registrars (n = 52), and specialists (n = 8). The majority of participants were aware of the role of folic acid in reducing teratogenicity of antiepileptic drugs (AEDs) (89%) and that women with epilepsy (WWE) should not stop taking their AEDs during pregnancy (76.6%). Two-thirds of participants knew that most WWE have healthy children (68.2%) and that enzyme-inducing AEDs may reduce effectiveness of some contraceptives (72.1%). Half of participants were aware of the association between AEDs and osteomalacia (50%), and more than one-third (38.3%) knew that women taking AEDs can safely breastfeed (38.3%). Few of them (20.1%) knew that WWE have a higher incidence of sexual dysfunction compared with women without epilepsy, and only some (15.6%) knew that estrogen has a proconvulsant effect while progesterone has anticonvulsant qualities. The mean score of our participants was 5.53 out of 10 (standard deviation (SD) ± 1.64). Only registrars with the highest mean knowledge (6.15 ± 1.26) were statistically different from the rest of the medical degree groups. ConclusionsIn this small cross-sectional study, Sudanese doctors' knowledge was not satisfactory regarding the majority of questions on KOWIE II. Further education and training are indicated to decrease this knowledge gap and to improve care of WWE.

The morbidity of sexual dysfunction of 125 Chinese women following different types of radical hysterectomy for gynaecological malignancies

Due to early detection and effective treatment, quality of sexual life of patients with gynaecological malignancies has become an important issue. However, the morbidity of sexual dysfunction and the proportion of different kinds of sexual dysfunction after radical hysterectomy are unclear. The aim of the current study was to assess the morbidity of sexual dysfunction and to conduct multivariate logistic regression analysis of patients' sexual dysfunction. Between July 2007 and December 2012, 125 women underwent radical hysterectomy, modified radical hysterectomy, and nerve-sparing radical hysterectomy were administered a self-reported sexual function questionnaire. The preoperative, and 1- and 2-year postoperative sexual dysfunction rates were 50.5% (50/99), 86.9% (93/107), and 92.3% (72/78), respectively. The incidence rates of sexual desire disorders before operation, at postoperative year 1, and at postoperative year 2 were 14.7% (14/95), 42.1% (45/107), and 51.9% (40/77), respectively. The preoperative incidence rates of sexual arousal disorders, orgasmic disorders, and sexual pain disorders were 18.4% (18/98), 51.1% (48/94), and 10.9% (11/101), respectively. At postoperative years 1 and 2, these were 38.8% (31/80), 81.0% (64/79), and 24.4% (20/82), and 49.1% (26/53), 84.6% (44/52), and 30.2% (16/53), respectively. Multivariable regression analysis revealed that age, preserved ovary, preserved posterior vaginal wall length, preoperative stage, radiotherapy, and education background were risk factors associated with sexual dysfunction. The patients following radical hysterectomy had a high incidence of sexual dysfunction, which plateaued in postoperative years1 and 2.

Frequency of Erectile Dysfunction in Males with Central Serous Chorioretinopathy

ABSTRACTObjectives: To evaluate the frequency of sexual dysfunction and associated factors in patients with central serous chorioretinopathy (CSCR). Material and methods: Fifty-eight CSCR patients who met the inclusion criteria and 99 age- and sex-matched healthy controls were prospectively investigated for sexual dysfunction and associated factors. All participants were investigated using the Beck Depression Inventory (BDI), Beck Anxiety Scale (BAS), and the15-question Index of Erectile Function-15 (IIEF-15) and by extensive examination of CSCR, associated factors, and confounding factors. Results: The mean ages of the patient and control groups were 46.95±11.27 and 45.3±10.93 years, respectively (p=0.370). The erectile function, orgasmic function, sexual desire, sexual satisfaction, and overall sexual satisfaction scores of the patient group were significantly lower than those of the control group (p<0.001). Severe erectile dysfunction (ED) was diagnosed in 3 (5.2%), moderate ED in 10 (17.2%), mild-to-moderate ED in 7 (12.1%), and mild ED in 15 (25.9%) patients in the patient group, whereas no severe or moderate ED was diagnosed in the control group. The erectile function score was found to be negatively correlated with age and BMI. No sexual parameters were found to be correlated with choroidal thickness (CT) in either the patient or control group. Conclusion: CSCR patients experience a higher incidence of sexual dysfunction compared to healthy individuals without CSCR. The exclusion of confounding factors suggests that factors involved in CSCR pathogenesis may also play a role in ED.

Psychotropic medication-induced sexual dysfunction and its interference with patient′s daily performance: a cross-sectional study

Objectives There are very few studies, especially in the Indian population, addressing the frequency of sexual dysfunction due to psychotropic medications. Therefore, this study aimed to quantify the frequency of sexual dysfunction and its interference in the patients' daily performance in a hospital-based population taking psychotropic medications. Materials and methods This cross-sectional study was conducted in the psychiatric unit of a Tertiary Care Teaching Hospital in South India over a period of 2 years. The Udvalg for Kliniske Undersogelser side effect rating scale was used to determine sexual dysfunction. A global assessment of interference in daily performance due to side effects was also evaluated. Results The overall incidence of sexual dysfunction was 20.95%. A higher incidence of sexual dysfunction was observed in women [n = 56 (70.88%)] and in the age group 18-29 years [n = 30 (37.9%)]. Amenorrhea [n = 32 (38.5%)] was the most prominently observed sexual dysfunction, followed by galactorrhea [n = 15 (18.07%)] and decreased sexual desire [n = 14 (16.86%)]. Antipsychotics [n = 54 (65.06%)] constituted the most common class of drug implicated in sexual dysfunction, followed by antidepressants [n = 25 (30.12%)]. Withdrawal of the drug [n = 58 (42%)] was the most common intervention for the management of sexual dysfunction. The majority of reports rated interference in daily performance due to side effects as severe [n = 48 (60.75%)], followed by moderate [n = 26 (32.91%)]. Conclusion The incidence rate of sexual dysfunction was 20.95%. Amenorrhea and galactorrhea were the two most prominent sexual dysfunctions affecting the patients with psychotropic medications. Thus it is important for all healthcare professionals to acknowledge and encourage discussion as well as the impact of drugs on sexual function.

Sexual dysfunctions and lower urinary tract symptoms in ankylosing spondylitis

To determine sexual dysfunctions and urinary symptoms in male ankylosing spondylitis (AS) patients and their association with various disease and patient factors. In this prospective case control study conducted at a tertiary care teaching institution, 100 males with AS were compared to 100 controls using International Index of Erectile Function-15 (IIEF), International Prostate Symptom Score (IPSS), Hospital Anxiety and Depression Scale (HADS) and a global question for overall relationship with their partners. Bath AS Functional Index (BASFI), visual analogue scale pain scores, patient global assessment scale and Bath AS Disease Activity Index were also assessed in the AS group. Chi-square test, unpaired t-test and univariate and multivariate binary logistic regression analyses were used to analyze the data. Anxiety, depression, erectile dysfunction (ED), orgasmic dysfunction, intercourse dissatisfaction, overall sexual dissatisfaction, altered overall relationship with partner and lower urinary tract symptoms (LUTS) were significantly (P < 0.05) higher in the AS group as compared to controls. Sexual desire, severe LUTS and bothersome LUTS (quality of life score > 2) were not different (P = 0.76, 0.82 and 0.30 respectively) between the two groups. ED was associated with anxiety, depression, longer disease duration, higher BASFI and higher age in AS patients (P = 0.02, 0.001, 0.02, 0.003 and 0.001 respectively). AS is associated with higher incidence of sexual dysfunction in male patients. ED is associated with anxiety, depression, longer duration of disease, higher BASFI score and higher age in AS patients.